Both a substantial reduction of CD8+ T cell counts in peripheral blood, and hyperactivation with extensive expression of surface activation markers (HLA-DR and CD38) and cytotoxic granules in CD8+ T cells are commonly observed in COVID-19 patients (139, 168). This evidence concerns the gene CD8A and COVID-19.